Nearly 150,000 people in the Netherlands suffer from type 1 diabetes. In this disease, the insulin-producing β-cells in the islets of Langerhans of the pancreas are destroyed by an autoimmune reaction. Patients require lifelong insulin injections, often multiple times daily, and are at a high risk for secondary conditions, including blindness and kidney failure. Current treatments help manage the absence of islets, but there is no cure. The RegMed XB partners are working towards a proof-of-concept of a new therapy for type 1 diabetes.